RT Journal Article
T1 In vitro antibacterial capacity and cytocompatibilityof SiO2–CaO–P2O5 meso-macroporous glassscaffolds enriched with ZnO†
A1 Sánchez-Salcedo, Sandra
A1 Shruti, Shruti
A1 Salinas Sánchez, Antonio J.
A1 Malavasi, Gianluca
A1 Menabue, Ledi
A1 Vallet Regí, María Dulce Nombre
AB Zn2+ ions exhibit osteogenic, angiogenic and antimicrobial properties. For this reason, they are often added in small amounts to bioceramics being investigated for bone tissue engineering. In this paper, the cytocompatibility and antibacterial properties of 80% SiO2–15% CaO–5% P2O5 (mol%) mesoporous bioactive glass (MBG) scaffolds substituted with 4.0% and 7.0% of ZnO were studied and compared with the Zn- free scaffold. Cell proliferation, morphology, differentiation and cytotoxic effects of Zn2+ ions released from the samples were examined by culturing human osteoblast-like cells (HOS) osteoblasts both in the presence of sample extracts and on the scaffold surface. The bacterial inhibition capacity of the scaffolds was explored by using Gram-positive Stapylococcus aureus bacteria, responsible for numerous infections in orthopedic surgery, to simulate a severe infection. Our results show that the Zn-MBG scaffolds possess a hierarchical meso-macropore structure suitable for osteoblast growth. Furthermore, the amount of Zn2+ released from the scaffold with 4.0% ZnO was found to be more favorable for HOS cell development than that released from the scaffold including 7.0% ZnO. Zn2+released to the medium from both scaffolds exhibited antibacterial properties against S. aureus. Thus, the cytocompatibility and the antibacterial ability exhibited by the MBG scaffold containing 4.0% ZnO make it a suitable candidate for bone regeneration applications.
PB The Royal Society of Chemistry
SN 2050-750X
YR 2014
FD 2014
LK https://hdl.handle.net/20.500.14352/34724
UL https://hdl.handle.net/20.500.14352/34724
LA eng
NO Comunidad de Madrid
NO Ministerio de Ciencia e Innovación (MICINN)
NO Ministerio de Economía y Competitividad (MINECO)
DS Docta Complutense
RD 29 abr 2024